ReShape Lifesciences Inc. has entered into an Equity Distribution Agreement with Maxim Group LLC to act as the exclusive sales agent for the issuance and sale of up to $9.7 million of the company's common stock. These shares will be offered in an at-the-market public offering, utilizing the company's existing shelf registration statement. The agreement allows for sales through methods defined under Rule 415 of the Securities Act of 1933, as well as privately negotiated transactions. Maxim Group will receive a 3.0% commission on the gross proceeds from the sales. The agreement includes provisions for reimbursement of legal expenses and allows for termination by either party under specified terms.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。